To analyze the outcomes of immunoembolization (IE) in patients with liver-dominant metastatic uveal melanoma (mUM) and compare these outcomes with those from the Phase 3 FOCUS trial evaluating melphalan via percutaneous hepatic perfusion, highlighting the significance of this comparison.
Key Findings:
Overall DCR was 27.9% (CR 4.7%, PR 20.9%, SD 2.3%) among 43 patients. Median PFS was 0.85 months; median OS was 32.7 months. One- and two-year OS rates were 69.8% and 55.8%, respectively. Patients with prior systemic therapy had improved outcomes compared to treatment-naïve patients.
Interpretation:
IE produced comparable overall survival outcomes to hepatic melphalan delivery despite lower radiographic response rates, suggesting it is a viable liver-directed therapy for liver-dominant mUM, with potential implications for treatment strategies.
Limitations:
Single-center study may limit generalizability; retrospective design may introduce selection bias; small sample size may affect the robustness of findings.
Conclusion:
IE is a promising liver-directed therapy for liver-dominant mUM, particularly in patients with prior systemic therapy. Prospective multicenter trials are needed to optimize treatment sequencing and validate these findings.
